Login to Your Account

Immune Takes Road Less Traveled with Epicept Buy

By Marie Powers
Staff Writer

Monday, August 26, 2013
Privately held Immune Pharmaceuticals Ltd. swam against the tide of biotechs rushing to initial public offerings (IPO) by completing its merger with Epicept Corp., gaining access to the public markets and an expanded pipeline of cancer and pain compounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription